385 related articles for article (PubMed ID: 15982921)
1. RET tyrosine kinase signaling in development and cancer.
Arighi E; Borrello MG; Sariola H
Cytokine Growth Factor Rev; 2005; 16(4-5):441-67. PubMed ID: 15982921
[TBL] [Abstract][Full Text] [Related]
2. RET receptor signaling: dysfunction in thyroid cancer and Hirschsprung's disease.
Asai N; Jijiwa M; Enomoto A; Kawai K; Maeda K; Ichiahara M; Murakumo Y; Takahashi M
Pathol Int; 2006 Apr; 56(4):164-72. PubMed ID: 16634961
[TBL] [Abstract][Full Text] [Related]
3. Rudolf-Virchow-Preis 1995. The role of RET proto-oncogene mutation analysis in the diagnosis of multiple endocrine neoplasia type 2 (MEN 2) gene carriers and in the discrimination of sporadic and familial medullary thyroid carcinomas and pheochromocytomas.
Komminoth P
Verh Dtsch Ges Pathol; 1995; 79():L-LV. PubMed ID: 8600671
[TBL] [Abstract][Full Text] [Related]
4. Glial cell line-derived neurotrophic factor differentially stimulates ret mutants associated with the multiple endocrine neoplasia type 2 syndromes and Hirschsprung's disease.
Carlomagno F; Melillo RM; Visconti R; Salvatore G; De Vita G; Lupoli G; Yu Y; Jing S; Vecchio G; Fusco A; Santoro M
Endocrinology; 1998 Aug; 139(8):3613-9. PubMed ID: 9681515
[TBL] [Abstract][Full Text] [Related]
5. Cys611Ser mutation in RET proto-oncogene in a kindred with medullary thyroid carcinoma and Hirschsprung's disease.
Nishikawa M; Murakumo Y; Imai T; Kawai K; Nagaya M; Funahashi H; Nakao A; Takahashi M
Eur J Hum Genet; 2003 May; 11(5):364-8. PubMed ID: 12734540
[TBL] [Abstract][Full Text] [Related]
6. Biological properties of Ret with cysteine mutations correlate with multiple endocrine neoplasia type 2A, familial medullary thyroid carcinoma, and Hirschsprung's disease phenotype.
Ito S; Iwashita T; Asai N; Murakami H; Iwata Y; Sobue G; Takahashi M
Cancer Res; 1997 Jul; 57(14):2870-2. PubMed ID: 9230192
[TBL] [Abstract][Full Text] [Related]
7. RET activation by germline MEN2A and MEN2B mutations.
Borrello MG; Smith DP; Pasini B; Bongarzone I; Greco A; Lorenzo MJ; Arighi E; Miranda C; Eng C; Alberti L
Oncogene; 1995 Dec; 11(11):2419-27. PubMed ID: 8570194
[TBL] [Abstract][Full Text] [Related]
8. The RET proto-oncogene: a challenge to our understanding of disease pathogenesis.
Kusafuka T; Puri P
Pediatr Surg Int; 1997; 12(1):11-8. PubMed ID: 9035202
[TBL] [Abstract][Full Text] [Related]
9. [From gene to disease; from the RET gene to multiple endocrine neoplasia types 2A and 2B, sporadic and familial medullary thyroid carcinoma, Hirschsprung disease and papillary thyroid carcinoma].
Hofstra RM; van der Luijt RB; Lips CJ
Ned Tijdschr Geneeskd; 2001 Nov; 145(46):2217-21. PubMed ID: 11757244
[TBL] [Abstract][Full Text] [Related]
10. Molecular mechanisms of RET activation in human cancer.
Santoro M; Melillo RM; Carlomagno F; Fusco A; Vecchio G
Ann N Y Acad Sci; 2002 Jun; 963():116-21. PubMed ID: 12095936
[TBL] [Abstract][Full Text] [Related]
11. Various mechanisms cause RET-mediated signaling defects in Hirschsprung's disease.
Pelet A; Geneste O; Edery P; Pasini A; Chappuis S; Atti T; Munnich A; Lenoir G; Lyonnet S; Billaud M
J Clin Invest; 1998 Mar; 101(6):1415-23. PubMed ID: 9502784
[TBL] [Abstract][Full Text] [Related]
12. Analysis of RET protooncogene point mutations distinguishes heritable from nonheritable medullary thyroid carcinomas.
Komminoth P; Kunz EK; Matias-Guiu X; Hiort O; Christiansen G; Colomer A; Roth J; Heitz PU
Cancer; 1995 Aug; 76(3):479-89. PubMed ID: 8625130
[TBL] [Abstract][Full Text] [Related]
13. RET proto-oncogene mutations in multiple endocrine neoplasia type 2 and medullary thyroid carcinoma.
Marsh DJ; Mulligan LM; Eng C
Horm Res; 1997; 47(4-6):168-78. PubMed ID: 9167949
[TBL] [Abstract][Full Text] [Related]
14. Molecular mechanisms of development of multiple endocrine neoplasia 2 by RET mutations.
Takahashi M; Asai N; Iwashita T; Murakami H; Ito S
J Intern Med; 1998 Jun; 243(6):509-13. PubMed ID: 9681851
[TBL] [Abstract][Full Text] [Related]
15. Mutations of the RET proto-oncogene in the multiple endocrine neoplasia type 2 syndromes, related sporadic tumours, and hirschsprung disease.
Eng C; Mulligan LM
Hum Mutat; 1997; 9(2):97-109. PubMed ID: 9067749
[TBL] [Abstract][Full Text] [Related]
16. Biological effects of the dual phenotypic Janus mutation of ret cosegregating with both multiple endocrine neoplasia type 2 and Hirschsprung's disease.
Arighi E; Popsueva A; Degl'Innocenti D; Borrello MG; Carniti C; Perälä NM; Pierotti MA; Sariola H
Mol Endocrinol; 2004 Apr; 18(4):1004-17. PubMed ID: 14715928
[TBL] [Abstract][Full Text] [Related]
17. RET mutations in human disease.
Pasini B; Ceccherini I; Romeo G
Trends Genet; 1996 Apr; 12(4):138-44. PubMed ID: 8901418
[TBL] [Abstract][Full Text] [Related]
18. The physical map of the human RET proto-oncogene.
Pasini B; Hofstra RM; Yin L; Bocciardi R; Santamaria G; Grootscholten PM; Ceccherini I; Patrone G; Priolo M; Buys CH
Oncogene; 1995 Nov; 11(9):1737-43. PubMed ID: 7478601
[TBL] [Abstract][Full Text] [Related]
19. Occurrence of MEN 2a in familial Hirschsprung's disease: a new indication for genetic testing of the RET proto-oncogene.
Decker RA; Peacock ML
J Pediatr Surg; 1998 Feb; 33(2):207-14. PubMed ID: 9498388
[TBL] [Abstract][Full Text] [Related]
20. Oncogenic activation of the ret protooncogene in thyroid cancer.
Takahashi M
Crit Rev Oncog; 1995; 6(1):35-46. PubMed ID: 8573606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
